Literature DB >> 17914065

Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families.

N Ertekin-Taner1, L H Younkin, D M Yager, F Parfitt, M C Baker, S Asthana, M L Hutton, S G Younkin, N R Graff-Radford.   

Abstract

OBJECTIVE: Plasma A beta levels are elevated in early-onset Alzheimer disease (AD) caused by autosomal dominant mutations. Our objective was to determine whether similar genetic elevations exist in late-onset AD (LOAD).
METHODS: We measured plasma A beta in first-degree relatives of patients with LOAD in a cross-sectional series and in extended LOAD families. We screened these subjects for pathogenic mutations in early-onset AD genes and determined their ApoE genotypes.
RESULTS: Plasma A beta is significantly elevated in the LOAD first-degree relatives in comparison to unrelated controls and married-in spouses. These elevations are not due to ApoE epsilon 4 or pathogenic coding mutations in the known early-onset AD genes.
CONCLUSIONS: The findings provide strong evidence for the existence of novel, as yet unknown genetic factors that affect late-onset Alzheimer disease by increasing A beta.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17914065     DOI: 10.1212/01.WNL.0000278386.00035.21

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  43 in total

Review 1.  Blood-based biomarkers for Alzheimer's disease: plasma Aβ40 and Aβ42, and genetic variants.

Authors:  Richard Mayeux; Nicole Schupf
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

2.  Relationship between inflammatory mediators, Aβ levels and ApoE genotype in Alzheimer disease.

Authors:  M Reale; M A Kamal; L Velluto; D Gambi; M Di Nicola; N H Greig
Journal:  Curr Alzheimer Res       Date:  2012-05       Impact factor: 3.498

3.  Latent structure and factorial invariance of a neuropsychological test battery for the study of preclinical Alzheimer's disease.

Authors:  N Maritza Dowling; Bruce Hermann; Asenath La Rue; Mark A Sager
Journal:  Neuropsychology       Date:  2010-11       Impact factor: 3.295

4.  Toward a plasma marker for Alzheimer disease: some progress, but still a long way to go.

Authors:  Howard A Crystal; Peter Davies
Journal:  Neurology       Date:  2008-02-19       Impact factor: 9.910

5.  Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease.

Authors:  Joseph L Price; Daniel W McKeel; Virginia D Buckles; Catherine M Roe; Chengjie Xiong; Michael Grundman; Lawrence A Hansen; Ronald C Petersen; Joseph E Parisi; Dennis W Dickson; Charles D Smith; Daron G Davis; Frederick A Schmitt; William R Markesbery; Jeffrey Kaye; Roger Kurlan; Christine Hulette; Brenda F Kurland; Roger Higdon; Walter Kukull; John C Morris
Journal:  Neurobiol Aging       Date:  2009-04-18       Impact factor: 4.673

6.  Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment.

Authors:  K Blennow; G De Meyer; O Hansson; L Minthon; A Wallin; H Zetterberg; P Lewczuk; H Vanderstichele; E Vanmechelen; J Kornhuber; J Wiltfang; I Heuser; W Maier; C Luckhaus; E Rüther; M Hüll; H Jahn; H J Gertz; L Frölich; H Hampel; R Pernetzki
Journal:  J Nutr Health Aging       Date:  2009-03       Impact factor: 4.075

7.  Change in plasma Aß peptides and onset of dementia in adults with Down syndrome.

Authors:  N Schupf; W B Zigman; M-X Tang; D Pang; R Mayeux; P Mehta; W Silverman
Journal:  Neurology       Date:  2010-11-02       Impact factor: 9.910

8.  Surface plasmon resonance binding kinetics of Alzheimer's disease amyloid beta peptide-capturing and plaque-binding monoclonal antibodies.

Authors:  Muthu Ramakrishnan; Karunya K Kandimalla; Thomas M Wengenack; Kyle G Howell; Joseph F Poduslo
Journal:  Biochemistry       Date:  2009-11-03       Impact factor: 3.162

9.  Plasma beta-amyloid and duration of Alzheimer's disease in adults with Down syndrome.

Authors:  V P Prasher; S G Sajith; P Mehta; W B Zigman; N Schupf
Journal:  Int J Geriatr Psychiatry       Date:  2010-02       Impact factor: 3.485

10.  Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study.

Authors:  T T Seppälä; S-K Herukka; T Hänninen; S Tervo; M Hallikainen; H Soininen; T Pirttilä
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-05-16       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.